MARK WRIGHT: Open Payments
NPI 1154448991 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$160,591 in 208 payments from 18 companies in 2025. Trend: 2023 $111,255 · 2024 $146,066 · 2025 $160,591
Honoraria: $89,500Speaker / faculty: $45,859Consulting: $10,080Travel & lodging: $8,685Food & beverage: $3,875Speaker / faculty: $2,363
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 64 | $67,245 |
| Neurocrine BioSciences, Inc. | 23 | $28,651 |
| Supernus Pharmaceuticals, Inc. | 38 | $21,580 |
| Alkermes, Inc. | 17 | $17,485 |
| Teva Pharmaceuticals USA, Inc. | 9 | $13,994 |
| Tris Pharma Inc | 14 | $8,316 |
| Noven Therapeutics, LLC | 10 | $2,632 |
| Corium, LLC | 8 | $146 |
| Collegium Pharmaceutical, Inc. | 6 | $118 |
| Otsuka America Pharmaceutical, Inc. | 4 | $93 |
Products named: Auvelity, INGREZZA, Qelbree, LYBALVI, AUSTEDO XR, Dyanavel XR, Xelstrym, REXULTI.
Industry payments across KY — which companies pay providers there.
